Ki-67 and p53 expression of the fallopian tube mucosa in breast cancer patients with hereditary risk

Archives of Gynecology and Obstetrics

Volumn 289, Issue 5, 2014, Pages 1079-1085

  Anton, Alina ^a   Schott, Sarah ^a   Kaip, Gisela ^a   Rath, Michelle ^a   Heil, Jörg ^a   Aulmann, Sebastian ^a   Sinn, Hans Peter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

BRCA1 risk; Fallopian tube; Fimbriae; Ovarian carcinogenesis

Indexed keywords

BRCA1 PROTEIN; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FIMBRIAE (UTERINE TUBE); GENE MUTATION; GENETIC RISK; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOLOGY; MEDICAL HISTORY; MIDDLE AGED; OVARY CANCER; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UTERINE TUBE; UTERINE TUBE MUCOSA;

ADULT; AGE FACTORS; AGED; ANIMALS; BREAST NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; MUCOUS MEMBRANE; MUTATION; OVARIAN NEOPLASMS; RISK; SOCIOECONOMIC FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900789857     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-013-3062-y     Document Type: Article

References (27)

1. Waldmann A, Eisemann N, Katalinic A (2013) Epidemiology of malignant cervical, corpus uteri and ovarian tumours - current data and epidemiological trends (Epidemiologie der bösartigen tumoren der inneren weiblichen genitalorgane - aktuelle zahlen und epidemiologische trends). Geburtsh Frauenheilk 73(02):123-129. doi:10.1055/s-0032-1328266
2. Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4(5):447-451
3. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385-394. doi:10.1016/S1470-2045(11)70404-1
4. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57(6):1457-1462
5. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D (1997) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15(1):103-105. doi:10.1038/ng0197-103 (Pubitemid 27014960)
6. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18):1365-1372 (Pubitemid 35154141)
7. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689 pii: S0002-9297(07) 63848-8
8. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646. doi:10.1126/science.1088759 (Pubitemid 37310920)
9. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P (2000) Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 76(1):45-50. doi:10.1006/gyno.1999.5623 (Pubitemid 30048318)
10. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA (2001) Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80(2):176-180. doi:10.1006/gyno.2000.6071 (Pubitemid 32158455)
11. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH (2001) Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451-456. doi:10.1002/path.1000 (Pubitemid 33069670)
12. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA (2001) A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 80(3):341-345. doi:10.1006/gyno.2000.6095 (Pubitemid 32207532)
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K (2002) Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-1615. doi:10.1056/NEJMoa020119 (Pubitemid 34755668)
14. Rebbeck TR (2002) Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. Eur J Cancer 38(Suppl 6):S15-S17 (pii: S0959804902002691)
15. Rutter JL, Wacholder S, Chetrit A, Lubin F, Menczer J, Ebbers S, Tucker MA, Struewing JP, Hartge P (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95(14):1072-1078 (Pubitemid 36950111)
16. Herrington CS, McCluggage WG (2010) The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 220(1):5-6. doi:10.1002/path.2630
17. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ (2006) Clinical and pathologic findings of prophylactic salpingooophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100(1):58-64. doi:10.1016/j.ygyno.2005.06.065 (Pubitemid 41815050)
18. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J (2005) Riskreducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23(1):127-132. doi:10.1200/JCO.2005.04.109 (Pubitemid 41702631)
19. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP (2008) A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 109(2):168-173. doi:10.1016/j.ygyno.2008.01.012
20. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP (2006) Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 13(1):1-7. doi:10.1097/01.pap.0000201826.46978.e5 (Pubitemid 44357143)
21. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30(2):230-236 (pii: 00000478-200602000-00012)
22. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25(10):1283-1289 (Pubitemid 32917122)
23. Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY (2005) BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 106(6):1327-1334. doi:10.1097/01.AOG.0000187892.78392. 3f (Pubitemid 41668953)
24. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih Ie M (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29(2):218-224 (pii: 00000478-200502000-00009)
25. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 93(2):301-306. doi:10.1016/j.ygyno.2004.01.043 (Pubitemid 38507593)
26. R Development Core Team (2011) R: a language and environment for statistical computing. Vienna
27. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 31(2):161-169. doi:10.1097/01.pas.0000213335.40358.47 (Pubitemid 46175016)